簡易檢索 / 詳目顯示

研究生: 路淑怡
Shu-Yi Lu
論文名稱: 以肝癌細胞為模式篩選具有調節血管新生相關因子的中草藥
Screening of Chinese Herbs with Anticancer Potential in Hepatocarcinoma Cells and Their Regulations of Angiogenesis and Metastasis
指導教授: 方剛
Fang, Kang
學位類別: 碩士
Master
系所名稱: 生命科學系
Department of Life Science
論文出版年: 2008
畢業學年度: 96
語文別: 中文
論文頁數: 100
中文關鍵詞: 肝癌中草藥血管新生
英文關鍵詞: hepatocarcinoma, Chinese medicine, angiogenesis
論文種類: 學術論文
相關次數: 點閱:237下載:25
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
  • 腫瘤細胞中,血管內皮細胞生長因子(vascular endothelial growth factor,VEGF)與基質金屬蛋白酶(matrix metalloproteinase,MMP)抑制劑可藉由許多不同的訊息傳遞路徑,達到具有抑制血管新生及細胞增生的效果。過去對於中草藥調節血管新生的作用機轉較少被探討。本研究使用各種不同中草藥投至人類肝癌細胞(HepG2及Huh 7),先以細胞存活率試驗初步篩選具生長抑制的藥物。實驗結果顯示,香蘇散及黃連解毒湯為複方中最具效力的待測中草藥。香蘇散能夠降低VEGF的蛋白質表現,並可藉由抑制MMP-9的RNA與蛋白質表現以抑制其蛋白質活性;初步判斷,其有效單方紫蘇葉藉由抑制VEGF表現以及MMP-9的活性以降低肝癌細胞的侵犯與血管新生作用。
    黃連解毒湯可以抑制β-catenin的蛋白質表現,其有效單方黃連,除了能抑制β-catenin蛋白質表現外也會調降MMP-9的蛋白質表現與活性。
    另外,單方藥物:石上柏、夏枯草、鴨膽子、苦參與黃獨均能抑制肝癌細胞生長;其中,夏枯草與黃獨亦能抑制VEGF表現,而鴨膽子與苦參是藉由抑制MMP-9及β-catenin的蛋白質表現以抑制肝癌細胞的侵犯與血管新生作用。
    本實驗以蛋白質體學的方法,篩選具有調節肝癌血管新生相關因子的中草藥,達到中草藥實證效應的目標。

    目錄 中文摘要------------------------------------------------------------I 英文摘要-----------------------------------------------------------III 壹、 緒論------------------------------------------------------------1 一、癌細胞增生、轉移與血管新生的關係------------------------------------1 二、影響血管新生的相關蛋白質------------------------------------------------3 三、中草藥研究的歷史沿革------------------------------------------------------6 四、研究目的-------------------------------------------------------------------------8 貳、 材料與方法---------------------------------------------------9 一、細胞培養-------------------------------------------------------------------------9 二、Total RNA萃取------------------------------------------------------------------9 三、反轉錄聚合酵素鏈反應-----------------------------------------------------11 四、蛋白質之萃取及定量--------------------------------------------------------12 五、西方轉漬法(Western blot)偵測血管新生調節因子-----------------13 六、中草藥複方或單方樣品的來源--------------------------------------------15 七、細胞存活率分析(MTT assay)------------------------------------------15 八、半數抑制濃度計算(IC50)------------------------------------------------16 九、細胞侵犯能力試驗(Invasion assay)-----------------------------------16 十、明膠酶譜法(Gelatinase Zymography)---------------------------------17 十一、資料分析(Data analysis)---------------------------------------------18 參、 結果-----------------------------------------------------------19 一、中草藥複方對肝癌細胞增生的影響-------------------------------------19 二、中草藥複方及其有效單方對肝癌細胞增生與血管新生的影響----20 三、中草藥單方對肝癌細胞增生與血管新生的影響----------------------25 肆、 討論-----------------------------------------------------------31 伍、 未來展望-----------------------------------------------------40 陸、 參考文獻-----------------------------------------------------41 圖目錄 圖一、(A)小柴胡湯(水萃取)處理HepG2細胞株之生長曲線-----------49 圖一、(B)小柴胡湯(70%酒精萃取)處理HepG2細胞株之生長曲線-50 圖一、(C)柴胡加龍骨牡蠣湯處理HepG2細胞株之生長曲線-------------51 圖一、(D)核桃承氣湯處理HepG2細胞株之生長曲線------------------------52 圖一、(E)半夏厚朴湯處理HepG2細胞株之生長曲線------------------------53 圖一、(F)香蘇散處理HepG2細胞株之生長曲線------------------------------54 圖一、(G)黃連解毒湯處理HepG2細胞株後之生長曲線--------------------55 圖一、(H)紫蘇葉處理HepG2細胞株後之生長曲線--------------------------56 圖一、(I)黃連處理HepG2細胞株後之生長曲線------------------------------57 圖一、(J)石上柏處理HepG2細胞株後之生長曲線---------------------------58 圖一、(K)夏枯草處理HepG2細胞株後之生長曲線--------------------------59 圖一、(L)鴨膽子處理HepG2細胞株後之生長曲線--------------------------60 圖一、(M)山慈菇處理HepG2細胞株後之生長曲線-------------------------61 圖一、(N)苦參處理HepG2細胞株後之生長曲線-----------------------------62 圖一、(O)黃獨處理HepG2細胞株後之生長曲線-----------------------------63 圖二、(A)香蘇散處理Huh 7細胞株之生長曲線------------------------------64 圖二、(B)黃連解毒湯處理Huh 7細胞株後之生長曲線----------------------65 圖二、(C)紫蘇葉處理Huh 7細胞株後之生長曲線----------------------------66 圖二、(D)黃連處理Huh 7細胞株後之生長曲線------------------------------67 圖二、(E)石上柏處理Huh 7細胞株後之生長曲線---------------------------68 圖二、(F)夏枯草處理Huh 7細胞株後之生長曲線----------------------------69 圖二、(G)鴨膽子處理Huh 7細胞株後之生長曲線---------------------------70 圖二、(H)山慈菇處理Huh 7細胞株後之生長曲線---------------------------71 圖二、(I)苦參處理Huh 7細胞株後之生長曲線-------------------------------72 圖二、(J)黃獨處理Huh 7細胞株後之生長曲線------------------------------73 圖三、HepG2 細胞侵犯能力實驗結果------------------------------------------74 圖四、中藥單方對HepG2 細胞侵犯能力實驗結果---------------------------75 圖五、Huh 7 細胞侵犯能力實驗結果--------------------------------------------76 圖六、中藥複方處理HepG2之血管新生相關蛋白表現-----------------------77 圖七、中藥單方處理HepG2之血管新生相關蛋白表現---------------------78 圖八、複方及其有效單方處理Huh 7之血管新生相關蛋白表現------------79 圖九、中藥單方處理Huh 7之血管新生相關蛋白表現------------------------80 圖十、MMP-9 PCR偵測中藥複方對於HepG2之RNA表現-------------------81 圖十一、複方及其有效單方對於HepG2之MMP活性測試-------------------82 圖十二、鴨膽子與苦參對於HepG2之MMP活性測試----------------------83 表目錄 表一、中草藥複方萃取物處理HepG2之IC50------------------------------------84 表二、中草藥單方萃取物處理HepG2之IC50------------------------------------85 表三、中草藥萃取物處理Huh 7之IC50-------------------------------------------86 表四、中草藥萃取物對於肝癌細胞血管新生相關蛋白的影響--------------87 附錄一、草藥配方----------------------------------------------------------------88

    al-Sereiti, M. R., K. M. Abu-Amer, et al. (1999). "Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials." Indian J Exp Biol 37(2): 124-30.
    Amalinei, C., I. D. Caruntu, et al. (2007). "Biology of metalloproteinases." Rom J Morphol Embryol 48(4): 323-34.
    Banno, N., T. Akihisa, et al. (2004). "Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects." Biosci Biotechnol Biochem 68(1): 85-90.
    Brown, L. F., M. Detmar, et al. (1997). "Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine." Exs 79: 233-69.
    Byrne, A. M., D. J. Bouchier-Hayes, et al. (2005). "Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)." J Cell Mol Med 9(4): 777-94.
    Carmeliet, P., N. Mackman, et al. (1996). "Role of tissue factor in embryonic blood vessel development." Nature 383(6595): 73-5.
    Chung, T. W., S. K. Moon, et al. (2004). "Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism." Faseb J 18(14): 1670-81.
    Cristofanilli, M., C. Charnsangavej, et al. (2002). "Angiogenesis modulation in cancer research: novel clinical approaches." Nat Rev Drug Discov 1(6): 415-26.
    Denekamp, J. (1984). "Vascular endothelium as the vulnerable element in tumours." Acta Radiol Oncol 23(4): 217-25.
    Drake, C. J., A. LaRue, et al. (2000). "VEGF regulates cell behavior during vasculogenesis." Dev Biol 224(2): 178-88.
    Eom, K. S., J. M. Hong, et al. (2008). "Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway." Biol Pharm Bull 31(4): 558-62.
    Esser, S., M. G. Lampugnani, et al. (1998). "Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells." J Cell Sci 111 ( Pt 13): 1853-65.
    Fang, X., R. C. Chang, et al. (2005). "Immune modulatory effects of Prunella vulgaris L." Int J Mol Med 15(3): 491-6.
    Fidler, I. J. (2002). "The organ microenvironment and cancer metastasis." Differentiation 70(9-10): 498-505.
    Folberg, R., V. Rummelt, et al. (1993). "The prognostic value of tumor blood vessel morphology in primary uveal melanoma." Ophthalmology 100(9): 1389-98.
    Fukamiya, N., M. Okano, et al. (1992). "Antitumor agents, 127. Bruceoside C, a new cytotoxic quassinoid glucoside, and related compounds from Brucea javanica." J Nat Prod 55(4): 468-75.
    Gomaa, A. I., S. A. Khan, et al. (2008). "Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis." World J Gastroenterol 14(27): 4300-8.
    Grondahl-Hansen, J., I. J. Christensen, et al. (1993). "High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis." Cancer Res 53(11): 2513-21.
    Hillen, F. and A. W. Griffioen (2007). "Tumour vascularization: sprouting angiogenesis and beyond." Cancer Metastasis Rev 26(3-4): 489-502.
    Houck, K. A., N. Ferrara, et al. (1991). "The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA." Mol Endocrinol 5(12): 1806-14.
    Houck, K. A., D. W. Leung, et al. (1992). "Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms." J Biol Chem 267(36): 26031-7.
    Hsu, Y. L., P. L. Kuo, et al. (2008). "Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo." J Gastroenterol Hepatol.
    Hu, J. P., K. Nishishita, et al. (2008). "Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways." Eur J Pharmacol 580(1-2): 70-9.
    Jankun, J., S. H. Selman, et al. (2006). "Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment." Oncol Rep 16(2): 341-6.
    Jing, L., L. Liu, et al. (2004). "Expression of myopodin induces suppression of tumor growth and metastasis." Am J Pathol 164(5): 1799-806.
    Joukov, V., V. Kumar, et al. (1998). "A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities." J Biol Chem 273(12): 6599-602.
    Jung, J. E., H. S. Kim, et al. (2007). "Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells." Carcinogenesis 28(8): 1780-7.
    Kim, S. U., D. Y. Kim, et al. (2008). "Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors." J Cancer Res Clin Oncol.
    Klagsbrun, M. and P. A. D'Amore (1996). "Vascular endothelial growth factor and its receptors." Cytokine Growth Factor Rev 7(3): 259-70.
    Kusunose, M., B. Qiu, et al. (2002). "Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats." Biol Pharm Bull 25(11): 1417-21.
    Lau, F. Y., C. H. Chui, et al. (2005). "Antiproliferative and apoptosis-inducing activity of Brucea javanica extract on human carcinoma cells." Int J Mol Med 16(6): 1157-62.
    Lee, H. and J. Y. Lin (1988). "Antimutagenic activity of extracts from anticancer drugs in Chinese medicine." Mutat Res 204(2): 229-34.
    Li, R., R. R. Walvekar, et al. (2008). "Unresectable hepatocellular carcinoma with a solitary metastasis to the mandible." Am Surg 74(4): 346-9.
    Lin, C. S., C. L. Kuo, et al. (2007). "Growth inhibitory and apoptosis inducing effect of Perilla frutescens extract on human hepatoma HepG2 cells." J Ethnopharmacol 112(3): 557-67.
    Lin, C. S., C. L. Kuo, et al. (2007). "Growth inhibitory and apoptosis inducing effect of Perilla frutescens extract on human hepatoma HepG2 cells." J Ethnopharmacol 112(3): 557-67.
    Lin, S., S. C. Tsai, et al. (2004). "Berberine inhibits HIF-1alpha expression via enhanced proteolysis." Mol Pharmacol 66(3): 612-9.
    Lin, Y., L. K. Ong, et al. (1995). "Differential in situ hybridization for determination of mutational specific expression of the p53 gene in human hepatoma cell lines." Pathology 27(2): 191-6.
    Liu, F. and T. B. Ng (2000). "Antioxidative and free radical scavenging activities of selected medicinal herbs." Life Sci 66(8): 725-35.
    Lu, J. S., Y. Q. Liu, et al. (2007). "[Protective effects and its mechanisms of total alkaloids from rhizoma Coptis chinensis on Helicobacter pylori LPS induced gastric lesion in rats]." Zhongguo Zhong Yao Za Zhi 32(13): 1333-6.
    Ma, Z., K. Otsuyama, et al. (2005). "Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells." Blood 105(8): 3312-8.
    McGowan, P. M. and M. J. Duffy (2008). "Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database." Ann Oncol.
    Mirzoeva, S., N. D. Kim, et al. (2008). "Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells." Mol Carcinog 47(9): 686-700.
    Paku, S. (1998). "Current concepts of tumor-induced angiogenesis." Pathol Oncol Res 4(1): 62-75.
    Pepper, M. S. and M. Skobe (2003). "Lymphatic endothelium: morphological, molecular and functional properties." J Cell Biol 163(2): 209-13.
    Renzulli, C., F. Galvano, et al. (2004). "Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2)." J Appl Toxicol 24(4): 289-96.
    Ryu, S. Y., M. H. Oak, et al. (2000). "Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris." Planta Med 66(4): 358-60.
    Shirataki, Y., N. Motohashi, et al. (2001). "In vitro biological activity of prenylflavanones." Anticancer Res 21(1A): 275-80.
    Su, B. N., L. C. Chang, et al. (2002). "Bioactive constituents of the seeds of Brucea javanica." Planta Med 68(8): 730-3.
    Sun, B., D. Zhang, et al. (2007). "Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma." Cancer Lett 249(2): 188-97.
    Takahashi, K., E. Uejima, et al. (2003). "In vitro inhibitory effects of Kampo medicines on metabolic reactions catalyzed by human liver microsomes." J Clin Pharm Ther 28(4): 319-27.
    Tapia, A., L. A. Salamonsen, et al. (2008). "Leukemia inhibitory factor promotes human first trimester extravillous trophoblast adhesion to extracellular matrix and secretion of tissue inhibitor of metalloproteinases-1 and -2." Hum Reprod 23(8): 1724-32.
    Tischer, E., R. Mitchell, et al. (1991). "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing." J Biol Chem 266(18): 11947-54.
    Tu, G., W. Xu, et al. (2008). "Progress in the development of matrix metalloproteinase inhibitors." Curr Med Chem 15(14): 1388-95.
    Wu, X. Z., G. R. Xie, et al. (2007). "Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma." J Gastroenterol Hepatol 22(8): 1178-82.
    Xiang, D., D. Wang, et al. (2006). "Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the beta-catenin/T-cell factor signaling." Anticancer Drugs 17(7): 753-62.
    Xu, F., Z. G. Ou-Yang, et al. (2006). "Sodium caffeate induces endothelial cell apoptosis and inhibits VEGF expression in cancer cells." Yao Xue Xue Bao 41(6): 572-6.
    Yoshiji, H., S. Kuriyama, et al. (2003). "Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development." Oncol Rep 10(4): 957-62.
    Yu, Z. L., X. R. Liu, et al. (2004). "[Anticancer effects of various fractions extracted from Dioscorea bulbifera on mice bearing HepA]." Zhongguo Zhong Yao Za Zhi 29(6): 563-7.
    Yurchenco, P. D. and J. C. Schittny (1990). "Molecular architecture of basement membranes." Faseb J 4(6): 1577-90.
    Zachary, I. (2001). "Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor." Am J Physiol Cell Physiol 280(6): C1375-86.
    Zhang, L. Z., Y. J. Guo, et al. (2008). "[A novel triterpenoid saponin from Prunella vulgaris]." Yao Xue Xue Bao 43(2): 169-72.
    Zhang, Q., X. Tang, et al. (2006). "Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells." Mol Cancer Ther 5(5): 1227-38.
    Zhang, S. D., Y. X. Fang, et al. (2007). "[Extraction and anti-tumor activity study of polysaccharide in several traditional Chinese medicine]." Zhong Yao Cai 30(2): 179-82.

    許鴻源(1985)簡明藥材學,新醫藥出版社(台灣)。

    謝明村(1996)中藥學概論,中國古典醫籍新解叢書(台北市)

    成佳憲,行政院衛生署,中醫藥委員會95年度計畫編號: CCMP95-RD-210中藥材黃連組成物對肺癌及肝癌放射線治療動物模式之免疫調控因子基因表現

    行政院衛生署,衛生統計資料(http://www.cichb.gov.tw/sta_information/sta_informations.asp)

    三七健康網(http://www.venterinternational.com/index.htm)

    QR CODE